Compare Manhattan Associates Inc (MANH) vs Oscar Health Inc (OSCR) Price & Performance

MANH trades at $191.05, down 2.37% on the day, but maintains a bullish technical outlook with strong moving average signals and support near $192. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, a legal investigation into fiduciary duties by Rosen Law Firm presents a headwind. Analyst consensus remains strongly bullish with a $210.33 price target and 80% buy ratings.

The stock offers upside potential from consistent earnings beats and cloud momentum, but faces risks from the ongoing legal probe and elevated valuation multiples. Net income is projected to dip slightly in 2026, necessitating careful monitoring of execution against guidance. The current price sits just above key support, with resistance at $199.

Oscar Health (OSCR) trades at $29.11, up 5.2% with strong recent earnings momentum, beating estimates in Q1 and Q2 2026. The stock shows bearish technical signals but benefits from record profitability and raised 2026 guidance. Revenue surged 70% to $4.9 billion in H1 2026, with net income turning positive at $551 million versus a 2025 loss. Valuation remains attractive with P/S of 0.53, suggesting potential undervaluation versus sector peers.

Outlook is positive given membership growth and cost discipline, but risks include medical cost volatility and competitive pressures. Analyst consensus price target of $32.50 implies 12% upside, though technical resistance near $30 may limit near-term gains. Execution on guidance and sustained margin expansion are key catalysts.